IRCT20180620040164N2 IRCT 2019-05-12 Aburaihan pharmaceutical co. Bioequivalence study of Ondansetron 4 mg film-coated tablet in 24 healthy male under fasting conditions Ondansetron Randomized, single-dose, crossover comparative bioequivalence study of Ondansetron 4 mg film-coated tablets of Aburaihan Pharmaceutical Co. and Zofran 4 mg film-coated tablet of Novartis Co. in 24 healthy male under fasting conditions 2018-12-22 anticipated 24 Complete https://irct.ir/trial/39170 interventional Randomization: Randomized, Blinding: Not blinded, Placebo: Not used, Assignment: Crossover, Purpose: Treatment, Randomization description: The sequence of taking test or reference product for each volunteer was determined according to the randomization schedule. The randomization schedule was prepared according to volunteer's allocated number. This number was allocated according to their entrance to volunteers' list in screening day. Bioequivalence Bioequivalence investigation of the generic (Aburaihan co.) Ondansetron 4 mg tablet with brand (Novartis co.) zofran 4 mg tablet.. Intervention 1: Intervention group (Test): Ondansetron 4 mg film-coated tablet, produced by Aburaihan pharmaceutical co. is the test product. In each period, 12 of 24 subjects will be given single oral dose of this product. Intervention 2: Intervention group (Reference): Ondansetron 4 mg film-coated tablet, produced by Novartis pharmaceutical co. is the reference product. In each period, 12 of 24 subjects will be given single oral dose of this product. Undecided - It is not yet known if there will be a plan to make this available Justification or reason for indecision in sharing IPD is There is no information.